<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mrj</journal-id><journal-title-group><journal-title xml:lang="ru">Современная ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Modern Rheumatology Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1996-7012</issn><issn pub-type="epub">2310-158X</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/1996-7012-2020-2-117-122</article-id><article-id custom-type="elpub" pub-id-type="custom">mrj-1024</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEWS</subject></subj-group></article-categories><title-group><article-title>Онкологическая настороженность у пациентов с ревматическими заболеваниями</article-title><trans-title-group xml:lang="en"><trans-title>Cancer alertness in patients with rheumatic diseases</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сычёва</surname><given-names>А. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Sycheva</surname><given-names>A. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Александра Сергеевна Сычёва</p><p>Кафедра терапии, клинической фармакологии и скорой медицинской помощи</p><p>127473, Москва, ул. Делегатская, 20, стр. 1</p></bio><bio xml:lang="en"><p>Aleksandra Sergeevna Sycheva</p><p>Department of Therapy, Clinical Pharmacology, and Emergency Medicine</p><p>20, Delegatskaya St., Build. 1, Moscow 127473</p></bio><email xlink:type="simple">docsycheva@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лила</surname><given-names>А. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Lila</surname><given-names>A. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>кафедра ревматологии ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования»</p><p>115522, Москва, Каширское шоссе, 34А125993, Москва, ул. Баррикадная, 2/1, стр. 1 </p></bio><bio xml:lang="en"><p>Department of Rheumatology, Russian Medical Academy of Continuing Professional Education</p><p>34A, Kashirskoe Shosse, Moscow 1155222/1, Barrikadnaya St., Build. 1, Moscow 125993 </p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Вёрткин</surname><given-names>А. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Vertkin</surname><given-names>A. L.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кафедра терапии, клинической фармакологии и скорой медицинской помощи</p><p>127473, Москва, ул. Делегатская, 20, стр. 1</p></bio><bio xml:lang="en"><p>Department of Therapy, Clinical Pharmacology, and Emergency Medicine</p><p>20, Delegatskaya St., Build. 1, Moscow 127473</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Хланта</surname><given-names>Д. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Khlanta</surname><given-names>D. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кафедра терапии, клинической фармакологии и скорой медицинской помощи</p><p>127473, Москва, ул. Делегатская, 20, стр. 1</p></bio><bio xml:lang="en"><p>Department of Therapy, Clinical Pharmacology, and Emergency Medicine</p><p>20, Delegatskaya St., Build. 1, Moscow 127473</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>30</day><month>05</month><year>2020</year></pub-date><volume>14</volume><issue>2</issue><fpage>117</fpage><lpage>122</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Сычёва А.С., Лила А.М., Вёрткин А.Л., Хланта Д.А., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Сычёва А.С., Лила А.М., Вёрткин А.Л., Хланта Д.А.</copyright-holder><copyright-holder xml:lang="en">Sycheva A.S., Lila A.M., Vertkin A.L., Khlanta D.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://mrj.ima-press.net/mrj/article/view/1024">https://mrj.ima-press.net/mrj/article/view/1024</self-uri><abstract><p>Различные по своей природе процессы, лежащие в основе патогенеза злокачественных новообразований (ЗН) и иммуновоспалительных ревматических заболеваний (РЗ), тем не менее имеют и некоторые общие черты. Так, многие неоплазии на начальных стадиях могут протекать под маской аутоиммунных болезней, что требует соблюдения принципа онкологической настороженности со стороны врачей разных специальностей. В ходе применения специфических методов лечения опухолей (иммуно- и цитостатической терапии, лучевой терапии) могут развиваться те или иные ревматические синдромы (артрит, миалгии, серозит и др.), требующие проведения дифференциальной диагностики. Вместе с тем течение ряда РЗ (ревматоидного артрита, синдрома Шёгрена, полимиозита) может сопровождаться развитием ЗН, что является актуальной проблемой для реальной клинической практики и требует дальнейшего изучения.Не менее важным остается факт общности этиологических факторов и генетической предрасположенности в развитии РЗ и ЗН. Вместе с тем врачам терапевтического профиля следует обращать внимание на наличие у многих ЗН ревматических «масок», что, несомненно, удлиняет время от появления первых симптомов до момента установления правильного диагноза.</p></abstract><trans-abstract xml:lang="en"><p>The processes that vary in nature and underlie the pathogenesis of malignant neoplasms (MNs) and immune-mediated inflammatory rheumatic diseases (RDs) share just the same some common features. Thus, many early-stage neoplasias can mask autoimmune diseases, requiring that physicians of various specialties should comply with the principle of cancer alertness. When specific cancer treatments (immunotherapy, cytostatic therapy, radiotherapy) are performed, there may be certain rheumatic syndromes (arthritis, myalgia, serositis, etc.) that require a differential diagnosis. At the same time, the course of a number of RDs (rheumatoid arthritis, Sjögren's syndrome, and polymyositis) can be accompanied by the development of MNs, which is relevant for real clinical practice and calls for further investigation.The community of etiological factors and a genetic predisposition in the development of RDs and MNs remain to be of no less importance. At the same time, therapists should pay attention to the presence of rheumatic masks in many MNs, which undoubtedly prolongs the time between onset of the first symptoms and correct diagnosis.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>ревматические заболевания</kwd><kwd>коморбидность</kwd><kwd>злокачественные новообразования</kwd><kwd>онкологическая настороженность</kwd></kwd-group><kwd-group xml:lang="en"><kwd>rheumatic diseases</kwd><kwd>comorbidity</kwd><kwd>malignant neoplasms</kwd><kwd>cancer alertness</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Galimberti F, Li Y, Fernandez AP. Clinically amyopathic dermatomyositis: clinical features, response to medications and malignancy-associated risk factors in a specific tertiary-care-centre cohort. Br J Dermatol. 2016 Jan; 174(1):158-64.</mixed-citation><mixed-citation xml:lang="en">Galimberti F, Li Y, Fernandez AP. Clinically amyopathic dermatomyositis: clinical features, response to medications and malignancy-associated risk factors in a specific tertiary-care-centre cohort. Br J Dermatol. 2016 Jan; 174(1):158-64.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Andras C, Levente B, Nagy-Vincze M, et al. Retrospective Analysis of CancerAssociated Myositis Patients over the Past 3 Decades in a Hungarian Myositis Cohort. Pathol Oncol Res. 2019 Oct 23. doi: 10.1007/s12253-019-00756-4. [Epub ahead of print].</mixed-citation><mixed-citation xml:lang="en">Andras C, Levente B, Nagy-Vincze M, et al. Retrospective Analysis of CancerAssociated Myositis Patients over the Past 3 Decades in a Hungarian Myositis Cohort. Pathol Oncol Res. 2019 Oct 23. doi: 10.1007/s12253-019-00756-4. [Epub ahead of print].</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Rahat MA, Shakya J. Parallel Aspects of the Microenvironment in Cancer and Autoimmune Disease. Mediators Inflamm. 2016;2016:4375120. doi: 10.1155/2016/4375120. Epub 2016 Feb 22.</mixed-citation><mixed-citation xml:lang="en">Rahat MA, Shakya J. Parallel Aspects of the Microenvironment in Cancer and Autoimmune Disease. Mediators Inflamm. 2016;2016:4375120. doi: 10.1155/2016/4375120. Epub 2016 Feb 22.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Bellan M, Boggio E, Sola D, et al. Association between rheumatic diseases and cancer: results from a clinical practice cohort study. Intern Emerg Med. 2017 Aug;12(5): 621-7. doi: 10.1007/s11739-017-1626-8. Epub 2017 Feb 8.</mixed-citation><mixed-citation xml:lang="en">Bellan M, Boggio E, Sola D, et al. Association between rheumatic diseases and cancer: results from a clinical practice cohort study. Intern Emerg Med. 2017 Aug;12(5): 621-7. doi: 10.1007/s11739-017-1626-8. Epub 2017 Feb 8.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Kleinert S, La Rosee P, Krü ger K. Rheumatoid symptoms in patients with hematologic neoplasms. Z Rheumatol. 2017 Oct;76(Suppl 2):38-45. doi: 10.1007/s00393017-0338-9</mixed-citation><mixed-citation xml:lang="en">Kleinert S, La Rosee P, Krü ger K. Rheumatoid symptoms in patients with hematologic neoplasms. Z Rheumatol. 2017 Oct;76(Suppl 2):38-45. doi: 10.1007/s00393017-0338-9</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Grignano E, Jachiet V, Fenaux P, et al. Autoimmune manifestations associated with myelodysplastic syndromes. Ann Hematol. 2018 Nov;97(11):2015-23. doi: 10.1007/s00277-018-3472-9. Epub 2018 Aug 8.</mixed-citation><mixed-citation xml:lang="en">Grignano E, Jachiet V, Fenaux P, et al. Autoimmune manifestations associated with myelodysplastic syndromes. Ann Hematol. 2018 Nov;97(11):2015-23. doi: 10.1007/s00277-018-3472-9. Epub 2018 Aug 8.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Ceribelli A, Isailovic N, De Santis M, et al. Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis. Clin Rheumatol. 2017 Feb;36(2): 469-75. doi: 10.1007/s10067-016-3453-0. Epub 2016 Oct 20.</mixed-citation><mixed-citation xml:lang="en">Ceribelli A, Isailovic N, De Santis M, et al. Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis. Clin Rheumatol. 2017 Feb;36(2): 469-75. doi: 10.1007/s10067-016-3453-0. Epub 2016 Oct 20.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Ahumada Pina H, Fuentes Cabrera L, Selame Glena R, et al. Dermatomyositis as the first manifestation of small cell carcinoma: case report and literature review. Medwave. 2016 Nov 15;16(10):e6609. doi: 10.5867/medwave.2016.10.6609</mixed-citation><mixed-citation xml:lang="en">Ahumada Pina H, Fuentes Cabrera L, Selame Glena R, et al. Dermatomyositis as the first manifestation of small cell carcinoma: case report and literature review. Medwave. 2016 Nov 15;16(10):e6609. doi: 10.5867/medwave.2016.10.6609</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Cho HG, Kuo KY, Xiao K, et al. Azathioprine and risk of multiple keratinocyte cancers. J Am Acad Dermatol. 2018 Jan;78(1):27-28.e1. doi: 10.1016/j.jaad.2017.09.063. Epub 2017 Oct 5.</mixed-citation><mixed-citation xml:lang="en">Cho HG, Kuo KY, Xiao K, et al. Azathioprine and risk of multiple keratinocyte cancers. J Am Acad Dermatol. 2018 Jan;78(1):27-28.e1. doi: 10.1016/j.jaad.2017.09.063. Epub 2017 Oct 5.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Khan S, Jain M, Mathur V, Feroz SM. Chronic Inflammation and Cancer: Paradigm on Tumor Progression, Metastasis and Therapeutic Intervention. Gulf J Oncolog. 2016 Jan;1(20):86-93.</mixed-citation><mixed-citation xml:lang="en">Khan S, Jain M, Mathur V, Feroz SM. Chronic Inflammation and Cancer: Paradigm on Tumor Progression, Metastasis and Therapeutic Intervention. Gulf J Oncolog. 2016 Jan;1(20):86-93.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Landgren AM, Landgren O, Gridley G, et al. Autoimmune disease and subsequent risk of developing alimentary tract cancers among 4.5 million US male veterans. Cancer. 2011 Mar 15;117(6):1163-71. doi: 10.1002/cncr.25524. Epub 2010 Nov 2.</mixed-citation><mixed-citation xml:lang="en">Landgren AM, Landgren O, Gridley G, et al. Autoimmune disease and subsequent risk of developing alimentary tract cancers among 4.5 million US male veterans. Cancer. 2011 Mar 15;117(6):1163-71. doi: 10.1002/cncr.25524. Epub 2010 Nov 2.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Correia NC, Girio A, Antunes I, et al. The multiple layers of non-genetic regulation of PTEN tumour suppressor activity. Eur J Cancer. 2014 Jan;50(1):216-25. doi: 10.1016/j.ejca.2013.08.017. Epub 2013 Sep 19.</mixed-citation><mixed-citation xml:lang="en">Correia NC, Girio A, Antunes I, et al. The multiple layers of non-genetic regulation of PTEN tumour suppressor activity. Eur J Cancer. 2014 Jan;50(1):216-25. doi: 10.1016/j.ejca.2013.08.017. Epub 2013 Sep 19.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Maria ATJ, Partouche L, Goulabchand R, et al. Intriguing Relationships Between Cancer and Systemic Sclerosis: Role of the Immune System and Other Contributors. Front Immunol. 2019 Jan 10;9:3112. doi: 10.3389/fimmu.2018.03112. eCollection 2018.</mixed-citation><mixed-citation xml:lang="en">Maria ATJ, Partouche L, Goulabchand R, et al. Intriguing Relationships Between Cancer and Systemic Sclerosis: Role of the Immune System and Other Contributors. Front Immunol. 2019 Jan 10;9:3112. doi: 10.3389/fimmu.2018.03112. eCollection 2018.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Okogbaa J, Batiste L. Dermatomyositis: An Acute Flare and Current Treatments. Clin Med Insights Case Rep. 2019 Jun 18;12: 1179547619855370. doi: 10.1177/1179547619855370. eCollection 2019.</mixed-citation><mixed-citation xml:lang="en">Okogbaa J, Batiste L. Dermatomyositis: An Acute Flare and Current Treatments. Clin Med Insights Case Rep. 2019 Jun 18;12: 1179547619855370. doi: 10.1177/1179547619855370. eCollection 2019.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Lundberg IE, Tjärnlund A, Bottai M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017 Dec;76(12):1955-64. doi: 10.1136/annrheumdis-2017-211468</mixed-citation><mixed-citation xml:lang="en">Lundberg IE, Tjärnlund A, Bottai M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017 Dec;76(12):1955-64. doi: 10.1136/annrheumdis-2017-211468</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Leatham H, Schadt C, Chisolm S, et al. Evidence supports blind screening for internal malignancy in dermatomyositis: Data from 2 large US dermatology cohorts. Medicine (Baltimore). 2018 Jan;97(2):e9639. doi: 10.1097/MD.0000000000009639</mixed-citation><mixed-citation xml:lang="en">Leatham H, Schadt C, Chisolm S, et al. Evidence supports blind screening for internal malignancy in dermatomyositis: Data from 2 large US dermatology cohorts. Medicine (Baltimore). 2018 Jan;97(2):e9639. doi: 10.1097/MD.0000000000009639</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Di Rollo D, Abeni D, Tracanna M, et al. Cancer risk in dermatomyositis: a systematic review of the literature. G Ital Dermatol Venereol. 2014 Oct;149(5):525-37. Epub 2014 Jun 30.</mixed-citation><mixed-citation xml:lang="en">Di Rollo D, Abeni D, Tracanna M, et al. Cancer risk in dermatomyositis: a systematic review of the literature. G Ital Dermatol Venereol. 2014 Oct;149(5):525-37. Epub 2014 Jun 30.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Qiang JK, Kim WB, Baibergenova A, Alhusayen R. Risk of Malignancy in Dermatomyositis and Polymyositis. J Cutan Med Surg. 2017 Mar/Apr;21(2):131-6. doi: 10.1177/1203475416665601. Epub 2016 Aug 20.</mixed-citation><mixed-citation xml:lang="en">Qiang JK, Kim WB, Baibergenova A, Alhusayen R. Risk of Malignancy in Dermatomyositis and Polymyositis. J Cutan Med Surg. 2017 Mar/Apr;21(2):131-6. doi: 10.1177/1203475416665601. Epub 2016 Aug 20.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Fang YF, Wu YJ, Kuo CF, et al. Malignancy in dermatomyositis and polymyositis: analysis of 192 patients. Clin Rheumatol. 2016 Aug;35(8):1977-84. doi: 10.1007/s10067-016-3296-8. Epub 2016 May 23.</mixed-citation><mixed-citation xml:lang="en">Fang YF, Wu YJ, Kuo CF, et al. Malignancy in dermatomyositis and polymyositis: analysis of 192 patients. Clin Rheumatol. 2016 Aug;35(8):1977-84. doi: 10.1007/s10067-016-3296-8. Epub 2016 May 23.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Dobloug GC, Garen T, Brunborg C, et al. Survival and cancer risk in an unselected and complete Norwegian idiopathic inflammatory myopathy cohort. Semin Arthritis Rheum. 2015 Dec;45(3):301-8. doi: 10.1016/j.semarthrit.2015.06.005. Epub 2015 Jun 17.</mixed-citation><mixed-citation xml:lang="en">Dobloug GC, Garen T, Brunborg C, et al. Survival and cancer risk in an unselected and complete Norwegian idiopathic inflammatory myopathy cohort. Semin Arthritis Rheum. 2015 Dec;45(3):301-8. doi: 10.1016/j.semarthrit.2015.06.005. Epub 2015 Jun 17.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Yamashita H, Ueda Y, Ozaki T, et al. Characteristics of 10 patients with paraneoplastic rheumatologic musculoskeletal manifestations. Mod Rheumatol. 2014 May;24(3): 492-8. doi: 10.3109/14397595.2013.843762. Epub 2013 Nov 5.</mixed-citation><mixed-citation xml:lang="en">Yamashita H, Ueda Y, Ozaki T, et al. Characteristics of 10 patients with paraneoplastic rheumatologic musculoskeletal manifestations. Mod Rheumatol. 2014 May;24(3): 492-8. doi: 10.3109/14397595.2013.843762. Epub 2013 Nov 5.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Batut RC, Juchet H, Tubery M, et al. ArletDermatopolymyosite et cancer: etude retrospective de 12 cas parmi une cohorte de 50. Evolution et facteurs predictifs. Rev Med Interne. 1998;19(Suppl. 1):120.</mixed-citation><mixed-citation xml:lang="en">Batut RC, Juchet H, Tubery M, et al. ArletDermatopolymyosite et cancer: etude retrospective de 12 cas parmi une cohorte de 50. Evolution et facteurs predictifs. Rev Med Interne. 1998;19(Suppl. 1):120.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Yu KH, Kuo CF, Huang LH, et al. Cancer Risk in Patients With Inflammatory Systemic Autoimmune Rheumatic Diseases: A Nationwide Population-Based Dynamic Cohort Study in Taiwan. Medicine (Baltimore). 2016 May;95(18):e3540. doi: 10.1097/MD.0000000000003540</mixed-citation><mixed-citation xml:lang="en">Yu KH, Kuo CF, Huang LH, et al. Cancer Risk in Patients With Inflammatory Systemic Autoimmune Rheumatic Diseases: A Nationwide Population-Based Dynamic Cohort Study in Taiwan. Medicine (Baltimore). 2016 May;95(18):e3540. doi: 10.1097/MD.0000000000003540</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Leipe J, Schulze-Koops H. Paraneoplastic syndromes in rheumatology. Internist (Berl). 2018 Feb;59(2):145-50. doi: 10.1007/s00108-017-0376-z.</mixed-citation><mixed-citation xml:lang="en">Leipe J, Schulze-Koops H. Paraneoplastic syndromes in rheumatology. Internist (Berl). 2018 Feb;59(2):145-50. doi: 10.1007/s00108-017-0376-z.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Giat E, Ehrenfeld M, Shoenfeld Y. Cancer and autoimmune diseases. Autoimmun Rev. 2017 Oct;16(10):1049-57. doi: 10.1016/j.autrev.2017.07.022. Epub 2017 Aug 1.</mixed-citation><mixed-citation xml:lang="en">Giat E, Ehrenfeld M, Shoenfeld Y. Cancer and autoimmune diseases. Autoimmun Rev. 2017 Oct;16(10):1049-57. doi: 10.1016/j.autrev.2017.07.022. Epub 2017 Aug 1.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Chakravarty SD, Markenson JA. Arthritis accompanying endocrine and metabolic disorders. In: Firestein GS, Budd RC, Gabriel SE, et al, editors. Kelley and Firestein's Textbook of Rheumatology. 10th ed. Elsevier; 2017.</mixed-citation><mixed-citation xml:lang="en">Chakravarty SD, Markenson JA. Arthritis accompanying endocrine and metabolic disorders. In: Firestein GS, Budd RC, Gabriel SE, et al, editors. Kelley and Firestein's Textbook of Rheumatology. 10th ed. Elsevier; 2017.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Machado RI, Braz Ade S, Freire EA. Incidence of neoplasms in the most prevalent autoimmune rheumatic diseases: a systematic review. Rev Bras Reumatol. 2014 Mar-Apr; 54(2):131-9.</mixed-citation><mixed-citation xml:lang="en">Machado RI, Braz Ade S, Freire EA. Incidence of neoplasms in the most prevalent autoimmune rheumatic diseases: a systematic review. Rev Bras Reumatol. 2014 Mar-Apr; 54(2):131-9.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Brito-Zeron P, Kostov B, Fraile G, et al. Characterization and risk estimate of cancer in patients with primary Sjögren syndrome. J Hematol Oncol. 2017 Apr 17;10(1):90. doi: 10.1186/s13045-017-0464-5</mixed-citation><mixed-citation xml:lang="en">Brito-Zeron P, Kostov B, Fraile G, et al. Characterization and risk estimate of cancer in patients with primary Sjögren syndrome. J Hematol Oncol. 2017 Apr 17;10(1):90. doi: 10.1186/s13045-017-0464-5</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Mercer LK, Regierer AC, Mariette X, et al. Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project. Ann Rheum Dis. 2017 Dec;76(12): 2025-30. doi: 10.1136/annrheumdis-2017211623. Epub 2017 Aug 19.</mixed-citation><mixed-citation xml:lang="en">Mercer LK, Regierer AC, Mariette X, et al. Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project. Ann Rheum Dis. 2017 Dec;76(12): 2025-30. doi: 10.1136/annrheumdis-2017211623. Epub 2017 Aug 19.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Hellgren K, Baecklund E, Backlin C, et al. Rheumatoid Arthritis and Risk of Malignant Lymphoma: Is the Risk Still Increased? Arthritis Rheum. 2017 Apr; 69(4):700-8. doi: 10.1002/art.40017.</mixed-citation><mixed-citation xml:lang="en">Hellgren K, Baecklund E, Backlin C, et al. Rheumatoid Arthritis and Risk of Malignant Lymphoma: Is the Risk Still Increased? Arthritis Rheum. 2017 Apr; 69(4):700-8. doi: 10.1002/art.40017.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Lee H. The Risk of Malignancy in Korean Patients with Rheumatoid Arthritis. Yonsei Med J. 2019 Feb;60(2):223-9. doi: 10.3349/ymj.2019.60.2.223</mixed-citation><mixed-citation xml:lang="en">Lee H. The Risk of Malignancy in Korean Patients with Rheumatoid Arthritis. Yonsei Med J. 2019 Feb;60(2):223-9. doi: 10.3349/ymj.2019.60.2.223</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Raaschou P, Simard JF, Holmqvist M, et al. Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden. BMJ. 2013 Apr 8;346:f1939. doi: 10.1136/bmj.f1939</mixed-citation><mixed-citation xml:lang="en">Raaschou P, Simard JF, Holmqvist M, et al. Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden. BMJ. 2013 Apr 8;346:f1939. doi: 10.1136/bmj.f1939</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Kostine M, Rouxel L, Barnetche T, et al. Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancerclinical aspects and relationship with tumour response: a single-centre prospective cohort study. Ann Rheum Dis. 2018 Mar;77(3): 393-8. doi: 10.1136/annrheumdis-2017212257. Epub 2017 Nov 16.</mixed-citation><mixed-citation xml:lang="en">Kostine M, Rouxel L, Barnetche T, et al. Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancerclinical aspects and relationship with tumour response: a single-centre prospective cohort study. Ann Rheum Dis. 2018 Mar;77(3): 393-8. doi: 10.1136/annrheumdis-2017212257. Epub 2017 Nov 16.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Yates WB, Vajdic CM, Na R, et al. Malignancy risk in patients with inflammatory eye disease treated with systemic immunosuppressive therapy: a tertiary referral cohort study. Ophthalmology. 2015 Feb;122(2): 265-73. doi: 10.1016/j.ophtha.2014.08.024. Epub 2014 Oct 11.</mixed-citation><mixed-citation xml:lang="en">Yates WB, Vajdic CM, Na R, et al. Malignancy risk in patients with inflammatory eye disease treated with systemic immunosuppressive therapy: a tertiary referral cohort study. Ophthalmology. 2015 Feb;122(2): 265-73. doi: 10.1016/j.ophtha.2014.08.024. Epub 2014 Oct 11.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Deepak P, Sifuentes H, Sherid M, et al. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factoralpha (TNF-α) inhibitors: results of the REFURBISH study. Am J Gastroenterol. 2013 Jan;108(1):99-105. doi: 10.1038/ajg.2012.334. Epub 2012 Oct 2.</mixed-citation><mixed-citation xml:lang="en">Deepak P, Sifuentes H, Sherid M, et al. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factoralpha (TNF-α) inhibitors: results of the REFURBISH study. Am J Gastroenterol. 2013 Jan;108(1):99-105. doi: 10.1038/ajg.2012.334. Epub 2012 Oct 2.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Liu Y, Fan W, Chen H, et al. Risk of breast cancer and total malignancies in rheumatoid arthritis patients undergoing TNF-α antagonist therapy: a meta-analysis of randomized control trials. Asian Pac J Cancer Prev. 2014;15(8):3403-10.</mixed-citation><mixed-citation xml:lang="en">Liu Y, Fan W, Chen H, et al. Risk of breast cancer and total malignancies in rheumatoid arthritis patients undergoing TNF-α antagonist therapy: a meta-analysis of randomized control trials. Asian Pac J Cancer Prev. 2014;15(8):3403-10.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Mercer LK, Galloway JB, Lunt M, et al. Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis. 2017 Mar;76(3):497-503. doi: 10.1136/annrheumdis-2016-209389. Epub 2016 Aug 8.</mixed-citation><mixed-citation xml:lang="en">Mercer LK, Galloway JB, Lunt M, et al. Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis. 2017 Mar;76(3):497-503. doi: 10.1136/annrheumdis-2016-209389. Epub 2016 Aug 8.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Bonovas S, Minozzi S, Lytras T et al. Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opin Drug Saf. 2016 Dec;15(sup1):35-54.</mixed-citation><mixed-citation xml:lang="en">Bonovas S, Minozzi S, Lytras T et al. Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opin Drug Saf. 2016 Dec;15(sup1):35-54.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Van der Heijde D, Zack D, Wajdula J, et al. Rates of serious infections, opportunistic infections, inflammatory bowel disease, and malignancies in subjects receiving etanercept vs. controls from clinical trials in ankylosing spondylitis: a pooled analysis. Scand J Rheumatol. 2014;43(1):49-53. doi: 10.3109/03009742.2013.834961. Epub 2013 Nov 1.</mixed-citation><mixed-citation xml:lang="en">Van der Heijde D, Zack D, Wajdula J, et al. Rates of serious infections, opportunistic infections, inflammatory bowel disease, and malignancies in subjects receiving etanercept vs. controls from clinical trials in ankylosing spondylitis: a pooled analysis. Scand J Rheumatol. 2014;43(1):49-53. doi: 10.3109/03009742.2013.834961. Epub 2013 Nov 1.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Wells AF, Curtis JR, Betts KA, et al. Systematic Literature Review and Metaanalysis of Tumor Necrosis Factor-Alpha Experienced Rheumatoid Arthritis. Clin Ther. 2017 Aug;39(8):1680-94.e2. doi: 10.1016/j.clinthera.2017.06.013. Epub 2017 Jul 20.</mixed-citation><mixed-citation xml:lang="en">Wells AF, Curtis JR, Betts KA, et al. Systematic Literature Review and Metaanalysis of Tumor Necrosis Factor-Alpha Experienced Rheumatoid Arthritis. Clin Ther. 2017 Aug;39(8):1680-94.e2. doi: 10.1016/j.clinthera.2017.06.013. Epub 2017 Jul 20.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Swierkot J, Lewandowicz-Uszynska A, Bogunia-Kubik K. Paraneoplastic syndromes and rheumatic diseases. Postepy Hig Med Dosw (Online). 2014 Jul 4;68:944-54.</mixed-citation><mixed-citation xml:lang="en">Swierkot J, Lewandowicz-Uszynska A, Bogunia-Kubik K. Paraneoplastic syndromes and rheumatic diseases. Postepy Hig Med Dosw (Online). 2014 Jul 4;68:944-54.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
